Kaufmann SH - Search Results

1

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.

De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. De Lorenzo SB, et al. Among authors: kaufmann sh. Front Oncol. 2013 Sep 11;3:228. doi: 10.3389/fonc.2013.00228. Front Oncol. 2013. PMID: 24062981 Free PMC article. Review.

2

Development of PARP inhibitors: an unfinished story.

Patel A, Kaufmann SH. Patel A, et al. Among authors: kaufmann sh. Oncology (Williston Park). 2010 Jan;24(1):66, 68. Oncology (Williston Park). 2010. PMID: 20187324 Free article. Review. No abstract available.

3

PARP inhibition: PARP1 and beyond.

Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. Rouleau M, et al. Among authors: kaufmann sh. Nat Rev Cancer. 2010 Apr;10(4):293-301. doi: 10.1038/nrc2812. Epub 2010 Mar 4. Nat Rev Cancer. 2010. PMID: 20200537 Free PMC article. Review.

4

Cancer. Targeting bacteria to improve cancer therapy.

Patel AG, Kaufmann SH. Patel AG, et al. Among authors: kaufmann sh. Science. 2010 Nov 5;330(6005):766-7. doi: 10.1126/science.1198310. Science. 2010. PMID: 21051622 No abstract available.

5

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells.

Patel AG, Sarkaria JN, Kaufmann SH. Patel AG, et al. Among authors: kaufmann sh. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11. doi: 10.1073/pnas.1013715108. Epub 2011 Feb 7. Proc Natl Acad Sci U S A. 2011. PMID: 21300883 Free PMC article.

6

Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells.

Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM. Huehls AM, et al. Among authors: kaufmann sh. Cancer Res. 2011 Jul 15;71(14):4944-54. doi: 10.1158/0008-5472.CAN-11-0814. Epub 2011 May 25. Cancer Res. 2011. PMID: 21613406 Free PMC article.

7

Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH. Patel AG, et al. Among authors: kaufmann sh. J Biol Chem. 2012 Feb 3;287(6):4198-210. doi: 10.1074/jbc.M111.296475. Epub 2011 Dec 12. J Biol Chem. 2012. PMID: 22158865 Free PMC article.

8

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Patel AG, et al. Among authors: kaufmann sh. Clin Cancer Res. 2012 Mar 15;18(6):1655-62. doi: 10.1158/1078-0432.CCR-11-2890. Epub 2012 Jan 30. Clin Cancer Res. 2012. PMID: 22291137 Free PMC article.

9

How does doxorubicin work?

Patel AG, Kaufmann SH. Patel AG, et al. Among authors: kaufmann sh. Elife. 2012 Dec 18;1:e00387. doi: 10.7554/eLife.00387. Elife. 2012. PMID: 23256047 Free PMC article.

10

Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.

Scott CL, Swisher EM, Kaufmann SH. Scott CL, et al. Among authors: kaufmann sh. J Clin Oncol. 2015 Apr 20;33(12):1397-406. doi: 10.1200/JCO.2014.58.8848. Epub 2015 Mar 16. J Clin Oncol. 2015. PMID: 25779564 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,195 results

Search Page